联合疗法在炎症性肠病中的应用进展
Research progress on combination therapy in inflammatory bowel disease
彭雯 1罗超 2孙志广1
作者信息
- 1. 南京中医药大学第二附属医院脾胃科,江苏 南京 210017;南京中医药大学
- 2. 南京中医药大学第二附属医院脾胃科,江苏 南京 210017
- 折叠
摘要
炎症性肠病(inflammatory bowel disease,IBD)是一种难治性肠道炎症性疾病,药代动力学的失效及药效学逃逸导致目前以单一靶向治疗为主的方案受到限制,而对于重症及肠外表现的治疗不尽如人意,加速了人们研究联合疗法的进度,既往比较成熟的联合治疗案例进一步推动双靶向治疗方案的研究,该文就 IBD联合疗法作一概述.
Abstract
Inflammatory bowel disease(IBD)is a refractory intestinal inflammatory disease,the failure of pharmaco-kinetics and pharmacodynamic evasion has led to the current single-targeted therapy based treatment is restricted,and the unsatisfactory treatment of severe and extraparenteral manifestations has accelerated the progress of research on com-bination therapy.The previous mature combination therapy cases have further promoted the research of dual-targeted therapy regimens.This article reviewed the combination therapy for IBD.
关键词
炎症性肠病/联合疗法/双靶向治疗Key words
Inflammatory bowel disease/Combination therapy/Dual-targeted therapy引用本文复制引用
基金项目
国家自然科学基金青年科学基金(82104792)
江苏省第二中医院中青年科技菁英项目(SEZJY2023014)
南京中医药大学自然科学基金(XZR2023067)
出版年
2024
NETL
NSTL
维普
万方数据